Physician profile
Brian Kadow
NPI 1386938157
$3,148.54
in general payments reported to CMS, 2019-2025
25 companies · $369 in 2025
The $369 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $288 · 2020: $156 · 2021: $247 · 2022: $491 · 2023: $671 · 2024: $927 · 2025: $369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,932 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,931.68 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $553.14 | 2019-2025 | Spaceoar Vue System - 10ml, Rezum Generator |
| Astellas Pharma US INC | $405.14 | 2019-2024 | Xtandi, Myrbetriq |
| Angiodynamics, INC. | $266.20 | 2021-2025 | Nanoknife, Solero |
| Olympus America INC. | $238.85 | 2020-2023 | Itind System |
| Teleflex LLC | $218.15 | 2021-2024 | Urolift |
| Medtronic, INC. | $191.20 | 2022-2023 | Interstim |
| Procept Biorobotics Corporation | $174.66 | 2024-2025 | Aquabeam System |
| Sumitomo Pharma America, INC. | $142.54 | 2023-2025 | Orgovyx, Gemtesa |
| Urogen Pharma, INC. | $140.07 | 2024 | |
| Bluewind Medical | $133.68 | 2024 | Revi |
| Neotract INC. | $121.43 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $108.63 | 2020-2024 | |
| Blue Earth Diagnostics | $90.34 | 2024 | |
| Halozyme INC | $75.23 | 2023 | |
| 180 Medical, INC. | $42.47 | 2025 | Gentlecath |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $36.84 | 2022-2023 | Aveed, Edex, Xiaflex |
| Astrazeneca Pharmaceuticals Lp | $35.06 | 2025 | Imfinzi |
| Ethicon US, LLC | $31.27 | 2021 | |
| Tolmar, INC. | $29.01 | 2023 | |
| Accord Healthcare, INC. | $23.09 | 2024 | |
| Urovant Sciences INC | $21.34 | 2022 | |
| Dendreon Pharmaceuticals LLC | $21.07 | 2025 | Provenge |
| Antares Pharma, INC. | $17.03 | 2023 | Nocdurna, Xyosted, Tlando |
| Myovant Sciences INC. | $16.69 | 2022 | |
| Endo USA, INC. | $15.41 | 2024 | Xiaflex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Kadow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.